The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

Pfizer and Bristol Myers Squibb are presented as attractively valued dividend stocks despite recent challenges. Both pharmaceutical companies face patent cliffs but have strong pipelines with promising candidates in oncology, weight loss, and anticoagulants. With forward yields of 7.1% and 4.3% respectively, and trading at discounted valuations (8.2x and 9x forward earnings), they are recommended as potential buys for dividend investors with $1,000 to deploy.

The cancer metabolism-based therapeutics market is projected to grow from $3.7 billion in 2026 to $26.3 billion by 2035, driven by precision medicine approaches and rising cancer prevalence. The market includes approximately 250 therapeutic programs targeting cancer metabolism vulnerabilities, with North America expected to hold over 45% market share. Key challenges include metabolic pathway complexity and cancer cell plasticity, while strategic collaborations are accelerating development.

The article compares two major healthcare stocks: Bristol Myers Squibb (BMY), a specialized biopharmaceutical company focused on oncology and immunology, and Johnson & Johnson (JNJ), a diversified healthcare giant with innovative medicine and medical device segments. While BMY trades at a significant valuation discount with a higher dividend yield (4.51%), JNJ is recommended as the better 2026 buy due to its stronger growth prospects, superior margins (28.5% vs 14.6%), robust free cash flow ($20B vs $12.8B), and more diversified revenue streams with 28 billion-dollar products. Both face patent cliff challenges and government price negotiation pressures.

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

Moderna's investigational flu vaccine candidate (mRNA-1010) received unanimous FDA advisory panel approval, with a regulatory decision expected by August 5. The stock has surged over 100% this year as the company reaches a key transition point with multiple product launches planned for 2027-2028. However, the analyst suggests waiting for a post-approval dip to buy, as much of the good news may already be priced in.

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

Pfizer stock fell 2.74% following the announcement that CFO Dave Denton will depart in August, raising investor concerns about leadership continuity and the company's ability to meet 2026 guidance. While recent drug approvals strengthen the pipeline, the CFO transition creates uncertainty around financial execution and earnings recovery.

The article recommends three healthcare dividend stocks for long-term investors: Bristol Myers Squibb, Merck, and Medtronic. Despite facing recent challenges like patent cliffs and competitive pressures, all three companies have strong dividend track records with consistent payout increases and promising pipelines to drive future growth.

Bristol Myers Squibb offers an attractive 4.5% dividend yield, well above market averages. While the company faces patent expirations on key drugs like Revlimid and Eliquis, its strong financial position, reasonable 72% payout ratio, investment-grade credit rating, and decades-long dividend history suggest the dividend is likely safe for most investors.

Bristol Myers Squibb has maintained an 18-year dividend growth streak despite facing patent cliffs on flagship drugs like Eliquis. The company's $3.5 billion in planned cost savings by 2027 and a sustainable 40% payout ratio support continued dividend growth. With $10.5 billion in cash reserves, BMY appears well-positioned to maintain and grow its 4.5% dividend yield.